Technical Analysis for ONTX - Onconova Therapeutics, Inc.

Grade Last Price % Change Price Change
C 0.87 4.52% 0.04
ONTX closed up 4.52 percent on Monday, March 18, 2024, on 1.18 times normal volume.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
Wide Bands Range Expansion 0.00%
MACD Bearish Signal Line Cross Bearish 4.52%
20 DMA Support Bullish 4.52%
1,2,3 Pullback Bullish Bullish Swing Setup 4.52%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 4.52%
Earnings Movers Other 4.52%
Wide Bands Range Expansion 4.52%
Earnings Movers Other -3.61%
Wide Bands Range Expansion -3.61%

   Recent Intraday Alerts

Alert Time
10 DMA Resistance about 8 hours ago
Non-ADX 1,2,3,4 Pullback Entry about 9 hours ago
1,2,3, Pullback Entry about 9 hours ago
Rose Above Previous Day's High about 9 hours ago
Rose Above 10 DMA about 9 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Onconova Therapeutics, Inc. Description

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drug candidates to treat cancer. Its products include Rigosertib intravenous (IV) that is in Phase III trials for higher risk myelodysplastic syndromes (MDS); Rigosertib Oral, which is Phase II clinical trials for patients with transfusion-dependent lower risk MDS and in patients with head and neck cancers; and Rigosertib IV, a combination therapy with gemcitabine in a Phase III clinical trials for the treatment of patients with metastatic pancreatic cancer. The company's products also comprise ON 013105 that is in Phase I clinical trials to treat various lymphomas and leukemias; and Recilisib, a molecule with radiation protection properties has completed four Phase I clinical trials. In addition, its preclinical products consist of ON 1231320, an inhibitor of polo-like kinase 2; ON 123300, an inhibitor of the cell cycle and cancer cell metabolism; ON 108600, an inhibitor of cyclin-dependent kinase 9 and casein kinase 2; ON 044580, a dual inhibitor of janus kinase 2 and Bcr-Abl kinase; ON 24 series of compounds that are oral anti-tubulin agents; and ON 146 series, which are selective inhibitors of PI3K alpha/delta isoforms. The company was founded in 1998 and is headquartered in Newtown, Pennsylvania.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Organic Compounds Chemical Compounds Lymphoma Radiation Pancreatic Cancer Leukemia Protein Kinase Inhibitor Cancer Cell Metabolism Myelodysplastic Syndrome Syndromes Head And Neck Cancer Pyridines Bemcentinib Cell Cycle Gemcitabine Kinase Tyrosine Kinase Inhibitors Combination Therapy Janus Kinase Piperazines Clinical Products Preclinical Products

Is ONTX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 1.45
52 Week Low 0.5509
Average Volume 71,434
200-Day Moving Average 0.82
50-Day Moving Average 0.75
20-Day Moving Average 0.84
10-Day Moving Average 0.91
Average True Range 0.07
RSI (14) 55.75
ADX 46.66
+DI 25.59
-DI 12.10
Chandelier Exit (Long, 3 ATRs) 0.84
Chandelier Exit (Short, 3 ATRs) 0.86
Upper Bollinger Bands 1.03
Lower Bollinger Band 0.65
Percent B (%b) 0.58
BandWidth 45.22
MACD Line 0.05
MACD Signal Line 0.05
MACD Histogram -0.0044
Fundamentals Value
Market Cap 18.27 Million
Num Shares 21 Million
EPS -0.96
Price-to-Earnings (P/E) Ratio -0.91
Price-to-Sales 64.59
Price-to-Book 1.01
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.05
Resistance 3 (R3) 1.05 1.00 1.02
Resistance 2 (R2) 1.00 0.96 1.00 1.01
Resistance 1 (R1) 0.94 0.93 0.97 0.93 1.00
Pivot Point 0.88 0.88 0.90 0.88 0.88
Support 1 (S1) 0.82 0.84 0.85 0.81 0.74
Support 2 (S2) 0.77 0.81 0.76 0.73
Support 3 (S3) 0.70 0.77 0.72
Support 4 (S4) 0.69